SAVA
Cassava Sciences Inc
NASDAQ · Pharmaceuticals
$2.03
+0.14 (+7.41%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 22.84M | 20.47M | 21.96M |
| Net Income | 4.14M | 5.17M | 4.25M |
| EPS | — | — | — |
| Profit Margin | 18.1% | 25.2% | 19.3% |
| Rev Growth | -6.9% | +1.2% | +18.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 43.58M | 40.03M | 39.84M |
| Total Equity | 32.33M | 29.33M | 28.67M |
| D/E Ratio | 1.35 | 1.36 | 1.39 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 7.09M | 5.98M | 7.27M |
| Free Cash Flow | 3.09M | 2.63M | 3.14M |